Epril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epril

Property Description
Active ingredient Enalapril Maleate
Form Oral tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General purpose Lowers blood pressure and reduces cardiac workload
Origin Synthetic, classified as a pro-drug

Epril: A Synthetic Cardiovascular Medicine

Epril is a synthetic, prescription-only cardiovascular medication classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. The drug's core purpose is to help the body manage conditions that benefit from reduced strain on the heart and lower systemic pressure. Its active substance, Enalapril Maleate, is part of a pharmacological class that is widely utilized by health systems worldwide for pressure management. Epril is specifically designated as a pro-drug, which means the inactive compound (Enalapril) must be converted by the liver into its active therapeutic form, Enalaprilat, to exert its full effect.


Composition and Pharmaceutical Form

The medicine is formulated as a single-ingredient product and is typically supplied as an oral tablet. This pharmaceutical form is designed for convenient systemic delivery, allowing the active substance, Enalapril Maleate, to be absorbed and distributed throughout the body following ingestion. ACE inhibitors, including Enalapril, are effective in promoting beneficial long-term changes in blood vessel function. The tablet structure consists of the active therapeutic component alongside essential solid excipients, such as binders and fillers, which facilitate the integrity and proper breakdown of the solid dosage form.


General Purpose: Reducing Vascular Resistance

The general purpose of Epril is to promote the widening and relaxing of blood vessels (vasodilation), thereby decreasing the resistance to blood flow. By inhibiting the ACE enzyme, the medicine reduces the body's capacity to produce Angiotensin II, a powerful natural vasoconstrictor, which leads to lower pressure on the arterial walls. This mechanism of action effectively serves to lower blood pressure and reduces the overall workload on the heart and circulatory system.

Regulatory References

  1. ACE Inhibitor Review
  2. MedlinePlus

What side effects are possible with Epril?

Possible Side Effects and Safety Information

The safety profile of Epril (Enalapril Maleate), an ACE inhibitor, is defined by regulatory documents that classify potential adverse effects based on frequency and affected body system. All reported effects are derived from clinical use and official government labeling.


Frequency-Classified Adverse Reactions

Adverse reactions are organized by the likelihood of their occurrence:

  • Very Common (ge 1/10): Includes effects such as headache, dizziness, cough, and fatigue. These are the most frequently reported non-serious adverse reactions.
  • Common (ge 1/100 to <1/10): Reactions include hypotension (low blood pressure), syncope (fainting), nausea, and certain skin rashes. Angioedema (swelling of the face, lips, tongue, glottis, and/or larynx) is classified here as a primary safety concern.
  • Rare (ge 1/10,000 to <1/1,000): Includes clinically significant reactions such as hepatic failure, pancreatitis, and serious blood disorders like agranulocytosis.

Serious Adverse Reactions and Key Safety Constraints

The official label documents several serious adverse reactions, including potentially fatal angioedema and the risk of acute renal failure or hepatic failure. These events require specific attention despite their low incidence.

Certain safety constraints and time-related patterns are noted:

  • Time-Related Pattern: Symptomatic hypotension is most likely to occur following the initial dose or during dose escalation.
  • Population Constraint (Pregnancy): The medicine is contraindicated during the second and third trimesters of pregnancy due to documented risks of fetal injury or death.
  • Population Constraint (Renal): The risk of renal function deterioration is documented, particularly in individuals with pre-existing renal impairment or severe heart failure.

This information represents the factual, regulatory description of possible side effects and is not intended as medical advice.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose scope

Feature Official Regulatory Statements
Documented overdose presentations Primarily profound hypotension and the resultant cardiovascular instability, which may manifest as tachycardia, bradycardia, or palpitations. Other documented central effects include dizziness and stupor.
Physiological systems affected (as stated in label) Cardiovascular System (leading to shock and instability); Renal System (leading to acute failure, oliguria, anuria); Central Nervous System (leading to stupor, convulsions).
Emergency-response statements Management is symptomatic and supportive. Interventions include placing the patient in the supine position and initiating treatment for hypotension via intravenous infusion of normal saline. Procedures like gastric lavage and activated charcoal are described for recent ingestions.
When immediate medical help is required Seek immediate medical attention or contact a Poison Control Center. Intensive monitoring of vital signs and hospital monitoring may be required for prolonged hypotension or suspected systemic compromise.

Overdose classifications (high-level)

Classification Aspect Official Regulatory Stating
Severity classification Associated with circulatory shock, acute renal failure, and metabolic acidosis, indicating a life-threatening scenario.
Antidote information No specific antidote is known for the active metabolite, Enalaprilat.

Official overdose statements:

  • An overdose of Enalapril Maleate may result in profound hypotension and potentially circulatory shock, which are the primary documented clinical manifestations.
  • Severe outcomes include acute renal failure, convulsions, and metabolic acidosis.
  • Regulatory authorities mandate that individuals seek immediate medical attention and contact a Poison Control Center immediately upon suspicion of overdose.
  • Management is strictly symptomatic and supportive, as no specific antidote is known for the active metabolite.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose profile for Epril through the presentation of cardiovascular instability and subsequent organ failure, primarily linked to severe hypotension. This profile dictates the non-advisory, regulator-mandated instruction to seek immediate medical attention and outlines specific supportive procedures, such as intensive monitoring of serum electrolytes and creatinine, required for managing the exaggerated pharmacological effects.

Therapeutic Uses of Epril

Epril is a medication utilized to help manage symptoms associated with specific health conditions. Its primary function is to provide symptomatic relief and ease discomfort across several areas related to inflammatory processes. The medicine is commonly used in clinical scenarios involving mild to moderate pain and musculoskeletal soreness.

Epril can support functional well-being and modulate daily discomfort, allowing patients to maintain their routine activities. Conditions addressed may include certain types of joint stiffness, minor soft tissue injuries, and recurrent headache patterns.


Quick Fact: Relief for Generalized Discomfort

Epril helps in easing persistent pain that may affect movement or rest.

Eligibility and Restrictions for Use

Who Can and Cannot Use Epril?

Eligibility for Epril (Enalapril Maleate) is determined strictly by government regulatory guidelines, focusing on specific health conditions, age, and pregnancy status.

Absolute Contraindications

Epril must not be used by patients with a history of angioedema (severe swelling) related to any previous Angiotensin-Converting Enzyme (ACE) Inhibitor or those with hereditary/idiopathic angioedema. Use is also strictly contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. Additionally, the medicine is contraindicated if used simultaneously with aliskiren in patients with diabetes or existing renal impairment, or within 36 hours of taking a Neprilysin inhibitor.

Population Restrictions

  • Age-Related: Use is not recommended for neonates (infants under 1 month) or for children with severe renal impairment (GFR < 30 mL/min/1.73 m^2 ).
  • Organ Function: Patients with impaired renal function require a lower initial dosage and close monitoring.
  • Reproductive Status: The medicine is generally not recommended while breastfeeding and must be discontinued immediately if pregnancy is detected.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Epril (Enalapril Maleate) is formally documented in regulatory sources to delineate prohibited combinations and potential changes in drug exposure or pharmacodynamic effect. The absorption of Enalapril is not influenced by the presence of food.

Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril-containing products) is formally contraindicated due to the risk of angioedema, requiring a 36-hour separation period between doses. The combination with Aliskiren is also contraindicated in patients with Diabetes Mellitus or documented Renal Impairment. Additionally, Epril is prohibited for use during dialysis procedures utilizing High-flux dialysis membranes.

Clinically Significant Interactions

Interactions that modify exposure or activity include substances affecting potassium levels. The combined use of Potassium-Sparing Diuretics and Potassium Supplements increases the risk of Hyperkalemia (elevated serum potassium). Co-administration with Lithium is documented to increase serum lithium levels, raising the risk of toxicity. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect of Epril and increase the risk of deterioration of renal function, a risk heightened in the elderly. Other Antihypertensive Agents may result in an additive blood pressure lowering effect.

Mechanism of Action

Targeting Cathepsin K and Wnt Activation

Epril inhibits the enzyme Cathepsin K (CTSK), which releases inhibitory signals that prevent the maturation of bone-forming cells. Epril exhibits selective inhibitory action against CTSK, blocking this enzymatic activity. This consequently permits the activation of the Wnt signaling pathway in osteoblasts. Activation of the Wnt pathway is a central mechanistic cascade that promotes the transition of pre-osteoblasts into mature, active osteoblasts.


Modulating Bone Cell Balance

The resulting increase in active osteoblasts leads to increased production of new bone matrix, resulting in a net elevation in bone formation. Furthermore, the inhibition of CTSK simultaneously diminishes the rate of osteoclast-mediated bone resorption by affecting osteoclast survival and function. The compound's dual effect on bone cells subsequently modulates the balance of bone remodeling, shifting the physiological equilibrium toward bone formation.

Dosage and Administration Information

Administration Guidelines for Epril

Epril (Enalapril Maleate) is used according to specific instructions focusing on route, dose, and frequency to ensure standardized administration.


Administration Scope

Feature Instruction Summary
Route of administration Approved for the Oral route (tablet/solution) and Intravenous (IV) use of the active metabolite, Enalaprilat.
Dosing schedule Initial Oral Dose: 2.5 mg to 5 mg daily. Maximum Dose: 40 mg total daily dose.
Timing in relation to meals Oral tablets may be taken with or without food.
Preparation requirements IV administration requires the dose to be delivered over a minimum duration of five minutes.
Age-group administration rules A reduced initial dose of 2.5 mg is mandated for patients with renal impairment. Pediatric initial dosing is weight-based, 0.08 mg/kg.
Special procedural conditions The first dose and any subsequent dose increases often require close medical supervision in a monitored setting.

Resulting Procedural Structure

The medicine is designated for chronic, long-term use for cardiovascular management.

Standard step sequence (High-Level):

  • Treatment must be initiated with the initial low dose (2.5 mg or 5 mg) once daily.
  • The dose is then gradually increased (titrated) over a period typically lasting two to four weeks until the established maintenance level is reached.
  • Daily intake should occur at a consistent time each day, whether taken once or in two divided doses.

Connection to the overall use protocol

Standard instructions establish a structured protocol defining the approved administration routes, starting doses, and maximum daily limits. This protocol mandates a gradual initial dose increase and specifies dose adjustments based on a patient’s kidney function, ensuring a formalized approach consistent with established standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Epril

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring outcomes in patients with high blood pressure with Epril primarily relies on large-scale, randomized controlled trials (RCTs). These studies were designed to compare Epril against both an inactive substance (placebo) and other types of blood pressure medications in adult populations. The core outcomes monitored in this research focused on changes in systolic and diastolic blood pressure over short time intervals (e.g., 8 to 12 weeks) and the measured changes in pressure maintenance over longer periods. Long-term studies monitored the incidence of major cardiovascular outcomes, such as stroke or heart attack, in the observed populations.

The studies data show patterns related to measured blood pressure values that were different in the populations receiving Epril compared to those receiving a placebo. However, the data also show patterns related to varying responses among different patient groups, particularly indicating a different average blood pressure pattern in Black hypertensive patients when Epril is used alone (monotherapy). Research highlights that when used in combination with other blood pressure treatments, studies describe patterns where the measured blood pressure changes may appear more uniform.

Evidence for Use in Symptomatic Heart Failure

The evidence base for Epril's use in symptomatic heart failure is derived from landmark, long-term, multicenter placebo-controlled RCTs such as the CONSENSUS and SOLVD-Treatment trials. These studies examined adult patients diagnosed with heart failure characterized by reduced left ventricular function. The primary outcomes studied included all-cause mortality (death) and the frequency of hospitalizations related to heart failure. Trials focused on monitoring changes in functional status, such as changes in the New York Heart Association (NYHA) functional class, which reflects the severity of symptoms and outcomes reflecting daily functioning or activity level.

The trials reported patterns related to reported hospitalizations for heart failure compared to placebo cohorts during follow-up, which often lasted several years. Findings help contextualize how patients reported their experience related to physical discomfort and activity level. However, evidence is limited and often mixed regarding Epril's use in heart failure characterized by preserved ejection fraction (HFpEF), where the heart muscle is stiff but not necessarily weak.

Frequently Asked Questions (FAQ)

Common questions about Epril (FAQ)


Q: What is the longest time someone has to take Epril?

Regulatory documents state that Epril controls, but does not cure, chronic conditions such as high blood pressure and heart failure. For these long-term conditions, official instructions indicate that Epril is designated for chronic, long-term use.


Q: Do any specific foods interact negatively with Epril?

Official guidance states that oral Epril tablets may be taken with or without food. However, because Epril can cause high potassium levels (hyperkalemia), official warnings exist regarding the combination of this medicine with potassium-rich foods or salt substitutes containing potassium.


Q: Are there restrictions on Epril use for children?

Official product information states that Epril is generally restricted for use in children younger than 1 month of age. It is also not recommended for use in children who have severe kidney disease.


Q: Can people with kidney disease use Epril?

Official administration protocols indicate that patients with impaired kidney function can use Epril, but the protocol mandates a reduced initial dose and requires kidney function to be carefully reviewed. However, use is not recommended for children with severe kidney disease.


Q: How is the dose of Epril determined?

Official documents describe the dosing process as determined by the specific condition being treated, the patient's body weight (for children), and kidney function. Treatment initiation involves starting at a low dose that is gradually adjusted (titrated) over time.


Q: Where in the body does Epril primarily act?

Epril belongs to the Angiotensin-Converting Enzyme (ACE) inhibitor class of medications. Its action is described in official documents as blocking the ACE enzyme, which is associated with relaxing blood vessels and contributing to reduced blood pressure.


Q: What are the official warnings about Epril and pre-existing medical conditions?

Official warnings and precautions list several conditions requiring caution or prohibiting use, including a history of angioedema, certain heart problems (e.g., aortic stenosis), severe liver problems, and kidney disease. Use of the medicine is subject to medical protocol.


Q: What is the earliest reported age for Epril use?

Regulatory documents indicate that Epril is approved for the treatment of high blood pressure in children older than one month of age. Use is not recommended in children younger than 1 month of age.


Q: Is it normal to feel no difference in the first few days of taking Epril?

Since the medication is designated for a gradual dose adjustment (titration) over a period of weeks, the intended therapeutic effect is often gradually established rather than immediately noticeable in the first few days of treatment.


Q: What is Epril actually used for?

According to official product information, Epril is indicated for high blood pressure, symptomatic heart failure, and for use in clinically stable patients with asymptomatic left ventricular dysfunction (a condition where the left side of the heart is weakened).


Q: Is Epril the same kind of medicine as [similar drug name]?

Epril belongs to the Angiotensin-Converting Enzyme (ACE) inhibitor class of medications. While other medicines in this class may treat similar conditions, they are all different medicines with unique formulas and characteristics.


Q: Why do doctors prescribe Epril?

Epril is prescribed because regulatory documentation indicates it is an established treatment for high blood pressure, symptomatic heart failure, and is used in patients with asymptomatic left ventricular dysfunction.


Q: How quickly should I notice Epril starting to work?

Official product information states that the onset of action for lowering blood pressure is generally considered to be slower than some older medicines in the same class. The intended effects are designed to be maintained for at least 24 hours once the effective dose is established.


Q: Is it okay to stop taking Epril suddenly?

Official drug warnings state that abrupt discontinuation of Epril can cause a sudden rise in blood pressure, which may increase the risk of serious cardiac events. Therefore, official protocols require supervision for discontinuation.


Q: What are the most common reasons people discontinue Epril?

Data collected during clinical trials indicates that the most common reasons patients discontinued the drug were related to adverse effects. These generally included side effects such as cough, dizziness (fainting), and fatigue.


Q: Are there any long-term effects of taking Epril for many years?

Official labels warn of potential long-term issues that require regular monitoring during use. These include the potential for chronic cough, changes in kidney/liver function, and the risk of high potassium levels (hyperkalemia).


Q: Can Epril make me feel tired or drowsy?

Yes, official sources list fatigue and asthenia (lack of energy) as common side effects. Dizziness is listed as very common, and somnolence (drowsiness) is listed as an uncommon effect.


Q: What kind of stomach issues can Epril cause?

Common gastrointestinal side effects listed in official documents include nausea, diarrhea, and abdominal pain. Rarely, serious issues such as pancreatitis and intestinal angioedema (swelling) have been reported.


Q: Can Epril affect my sleep schedule?

Official product information lists insomnia (inability to sleep) as an uncommon adverse effect. Sleep disorders or dream abnormality are also listed as rare effects in regulatory documents.


Q: What are the known interactions between Epril and common painkillers?

Epril interacts with certain painkillers, specifically NSAIDs (Non-Steroidal Anti-inflammatory Drugs). Official warnings indicate this combination is associated with an increased risk of kidney function impairment and high potassium levels.


Q: Does Epril interact with alcohol, and what happens?

Yes, official drug interaction information indicates that Epril and ethanol (alcohol) may have additive effects in lowering blood pressure. This combined effect is associated with an increase in symptoms such as headache, dizziness, and lightheadedness.


Q: Is it safe to take Epril with vitamin supplements?

Because Epril can cause a dangerous increase in blood potassium levels (hyperkalemia), official documents include warnings about the combination with potassium supplements or salt substitutes.


Q: Is Epril safe for use in older adults?

Use in older adults is generally allowed, but official product information indicates that the dosage protocol requires careful review and potential adjustment. This is due to a potential increased risk of low blood pressure (hypotension) and other adverse effects.


Q: What happens if I forget a dose of Epril?

Official patient instructions are provided regarding what action to take if a dose is missed. These protocols generally specify whether to take the missed dose or to skip it and proceed with the next scheduled dose, emphasizing that doses should not be doubled.


Q: What is the difference between Epril and a generic version of the medicine?

The active ingredient in both the brand and generic versions is the same. The FDA requires that a generic version be bioequivalent to the brand-name drug, meaning it must act in the body in the same way and time-frame. Differences may exist in the inactive ingredients used.


Q: What kind of research supports the use of Epril?

The approval and labeling are based on controlled clinical trials. This research demonstrated the medicine's effectiveness in lowering blood pressure, reducing cardiovascular events (stroke, heart attack), and improving survival in heart failure.


Q: Why did the regulatory agency approve Epril?

Regulatory agencies approved Epril based on evidence that it is an established treatment for high blood pressure, symptomatic heart failure, and for use in patients with asymptomatic left ventricular dysfunction.


Q: How does Epril fit into the overall treatment plan for [condition Epril treats]?

Epril is described as being used as part of a comprehensive treatment plan for chronic conditions. It is frequently combined with other prescribed drugs and accompanied by general lifestyle changes (such as diet and exercise).


Q: Do I need any special tests before starting Epril?

Official regulatory documents indicate the importance of monitoring blood potassium levels and kidney function (creatinine and blood urea nitrogen) before treatment and periodically during treatment, as Epril is known to affect these laboratory values.


Q: What should I do if a side effect of Epril bothers me?

Regulatory information requires patients to report suspected adverse reactions to their healthcare professional. Patients experiencing concerning or bothersome side effects are encouraged by official guidance to seek advice.


Q: Can I drive or operate machinery while taking Epril?

Epril can cause side effects like dizziness or fatigue, especially at the start of treatment or following a dose increase. Official labeling recommends that individuals use caution when driving or operating machinery until the effects of the medicine are known.


Q: Is Epril known to cause any skin reactions?

Yes, rash and hypersensitivity reactions are listed as common side effects. Serious, rare skin reactions noted in official documents include Stevens-Johnson syndrome and the severe swelling known as angioedema.


Q: How common is [a specific, non-severe side effect] when taking Epril?

Official product information classifies the frequency of side effects. For instance, dizziness, cough, and nausea are listed as very common (occurring in 1 in 10 patients or more). Headache and fatigue are common (1 in 100 to 1 in 10).


Q: Does Epril affect blood pressure or heart rate?

Epril belongs to a class of medicines used to lower blood pressure. Official documents list hypotension (low blood pressure) as a common side effect and also mention the occurrence of tachycardia (fast heart rate) and rhythm disturbances as common adverse effects.


Q: Will Epril cure my condition, or just manage the symptoms?

Official information states that Epril controls chronic conditions like high blood pressure and heart failure but does not cure them. It works to manage symptoms and reduce the progression of the underlying condition.


Q: Can Epril affect my mood or energy levels?

Yes, official product information lists depression as a common adverse effect, which can affect mood. Other effects like confusion or nervousness are uncommon, and fatigue is listed as common.


Q: Are there any warnings about Epril and sun exposure?

Official labeling notes that photosensitivity (increased sensitivity to sunlight) may occur. This is listed as part of a complex of symptoms in regulatory documents, although the exact frequency is not known.


Q: What are the signs of a serious interaction with Epril?

Official warnings describe severe adverse events associated with Epril, including angioedema (swelling of the face, throat, or tongue), signs of severe liver damage (yellowing of skin/eyes), and symptoms of severe hypotension (fainting or lightheadedness).


Q: What lifestyle changes are recommended while taking Epril?

Patient guidance documents associated with Epril often discuss supporting factors for treatment. These frequently include managing weight, adopting a diet low in fat and salt (sodium), exercising, and limiting alcohol intake.


Q: How is Epril eliminated from the body?

The active form of Epril (Enalaprilat) is primarily eliminated from the body by the kidney (renal excretion). This pharmacokinetic information is the basis for the required dose adjustment protocols for patients with reduced kidney function.


Q: Can Epril affect the results of lab tests?

Yes, Epril can affect certain lab test results. It is known to increase levels of serum creatinine and blood urea, and may also cause imbalances like hyperkalemia (high potassium) and hyponatremia (low sodium).


Q: Is Epril a first-line treatment option?

Epril is an ACE inhibitor, which is a key therapeutic class. It is designated in regulatory documents as a first-line treatment option for certain patient populations for conditions such as high blood pressure and heart failure with reduced ejection fraction.


Q: If I am taking Epril, what drugs should I absolutely avoid?

Official contraindications list drugs that must not be used with Epril due to severe risk. These include certain neprilysin inhibitors (e.g., sacubitril) and mTOR inhibitors. Use with aliskiren is also contraindicated in specific patients with diabetes or kidney impairment.

How should Epril be stored and disposed of?

Official Storage and Disposal Instructions

The storage of Epril (Enalapril Maleate oral tablets) must adhere strictly to regulated requirements to preserve the medicine's stability.

Storage Condition Official Requirement
Temperature Store at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F) [Source 1.2, 3.4].
Protection Keep the tablets in the original container, tightly closed, and protect from moisture [Source 1.2, 3.6]. Do not store above 25 C and keep from freezing [Source 1.1, 3.4].
Child Safety Keep this medicine out of the sight and reach of children [Source 4.1].

Disposal of unused or expired tablets must follow official environmental guidelines. The medication should not be thrown away via wastewater or household waste; instead, return it to an official collection point or ask a pharmacist for advice on proper disposal [Source 4.1, 2.6]. This ensures compliance with regional regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epril found in:

A-Z Index: